Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $1,022,338.40 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 36,460 shares of the company’s stock in a transaction on Wednesday, April 16th. The stock was sold at an average price of $28.04, for a total transaction of $1,022,338.40. Following the transaction, the chief executive officer now owns 92,103 shares of the company’s stock, valued at approximately $2,582,568.12. The trade was a 28.36 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Andrew Dudum also recently made the following trade(s):

• On Monday, March 17th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.98, for a total transaction of $4,353,755.46.
• On Tuesday, February 18th, Andrew Dudum sold 128,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29.
• On Friday, January 31st, Andrew Dudum sold 100,000 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.22, for a total value of $3,522,000.00.
• On Thursday, January 23rd, Andrew Dudum sold 27,098 shares of Hims & Hers Health stock. The shares were sold at an average price of $30.08, for a total value of $815,107.84.
• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total value of $9,000.00.

Hims & Hers Health Trading Up 1.1 %

NYSE:HIMS opened at $27.24 on Friday. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a market cap of $6.05 billion, a price-to-earnings ratio of 61.91 and a beta of 1.65. The company’s 50-day moving average is $37.26 and its two-hundred day moving average is $30.61.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in HIMS. SlateStone Wealth LLC boosted its stake in Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. grew its holdings in Hims & Hers Health by 100.0% in the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares during the period. Summit Investment Advisors Inc. increased its position in Hims & Hers Health by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock worth $480,000 after purchasing an additional 628 shares during the last quarter. Cim LLC raised its stake in Hims & Hers Health by 1.0% during the fourth quarter. Cim LLC now owns 71,869 shares of the company’s stock worth $1,738,000 after purchasing an additional 694 shares during the period. Finally, Harbour Investments Inc. boosted its holdings in shares of Hims & Hers Health by 18.8% in the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after purchasing an additional 833 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. Piper Sandler upped their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 25th. Needham & Company LLC increased their target price on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a report on Tuesday, February 25th. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Truist Financial dropped their price objective on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating for the company in a research note on Thursday, April 10th. Finally, Bank of America boosted their target price on Hims & Hers Health from $21.00 to $22.00 and gave the stock an “underperform” rating in a research report on Tuesday, March 18th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $38.25.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.